Talk:Tadalafil: Difference between revisions

(One intermediate revision by the same user not shown)

Line 5:

'''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED).<ref>{{cite web|url=https://www.~~mayoclinic~~.~~org~~/~~drugs-supplements~~/~~tadalafil-oral-route~~/~~description/drg-20068537|title=Tadalafil Oral|publisher=Mayo Clinic~~|access-date=~~January 24, 2023~~}}</ref> It is a post-synaptic [[agonist]] of the cGMP-specific phosphodiesterase type 5 (PDE5) enzyme, preventing cGMP breakdown and enhancing smooth muscle relaxation in the corpus cavernosum of the penis.<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/en/documents/product-information/cialis-epar-product-information_en.pdf|title=Cialis: EPAR Product Information|publisher=European Medicines Agency (EMA)|access-date=January 24, 2023}}</ref>

'''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and Pulmonary Arterial Hypertension (PAH).<ref name="hahappbig">{{cite web | last=Fahmy | first=George | last2=Hess | first2=Jaclyn | title=Tadalafil | publisher=StatPearls Publishing | date=2024-03-20 | pmid=38753929 | url=https://www.ncbi.nlm.nih.gov/books/NBK603743/ | access-date=2024-10-09}}</ref> It is a post-synaptic [[agonist]] of the cGMP-specific phosphodiesterase type 5 (PDE5) enzyme, preventing cGMP breakdown and enhancing smooth muscle relaxation in the corpus cavernosum of the penis.<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/en/documents/product-information/cialis-epar-product-information_en.pdf|title=Cialis: EPAR Product Information|publisher=European Medicines Agency (EMA)|access-date=January 24, 2023}}</ref>

[[File:Tadalafil_structure.png|thumb|Chemical Structure of Tadalafil]]

@@ Line 5: / Line 5: @@
 {{SubstanceBox/Tadalafil}}
-'''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED).<ref>{{cite web|url=https://www.mayoclinic.org/drugs-supplements/tadalafil-oral-route/description/drg-20068537|title=Tadalafil Oral|publisher=Mayo Clinic|access-date=January 24, 2023}}</ref> It is a post-synaptic [[agonist]] of the cGMP-specific phosphodiesterase type 5 (PDE5) enzyme, preventing cGMP breakdown and enhancing smooth muscle relaxation in the corpus cavernosum of the penis.<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/en/documents/product-information/cialis-epar-product-information_en.pdf|title=Cialis: EPAR Product Information|publisher=European Medicines Agency (EMA)|access-date=January 24, 2023}}</ref>
+'''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and Pulmonary Arterial Hypertension (PAH).<ref name="hahappbig">{{cite web | last=Fahmy | first=George | last2=Hess | first2=Jaclyn | title=Tadalafil | publisher=StatPearls Publishing | date=2024-03-20 | pmid=38753929 | url=https://www.ncbi.nlm.nih.gov/books/NBK603743/ | access-date=2024-10-09}}</ref> It is a post-synaptic [[agonist]] of the cGMP-specific phosphodiesterase type 5 (PDE5) enzyme, preventing cGMP breakdown and enhancing smooth muscle relaxation in the corpus cavernosum of the penis.<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/en/documents/product-information/cialis-epar-product-information_en.pdf|title=Cialis: EPAR Product Information|publisher=European Medicines Agency (EMA)|access-date=January 24, 2023}}</ref>
 [[File:Tadalafil_structure.png|thumb|Chemical Structure of Tadalafil]]